A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Stopped early · Phase 2
Conditions studied: C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN, Dense Deposit Disease
In brief
The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.
Key facts
- Study ID
- NCT03459443
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 22
- Starts
- 2018-06-20
- Expected to finish
- 2021-03-29
- Last updated by the study team
- 2023-08-21
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Study Site — Birmingham, Alabama, United States
- Clinical Study Site — Stanford, California, United States
- Clinical Study Site — New Haven, Connecticut, United States
- Clinical Study Site — Cincinnati, Ohio, United States
- Clinical Study Site — Columbus, Ohio, United States
- Clinical Study Site — Philadelphia, Pennsylvania, United States
- Clinical Study Site — Sydney, New South Wales, Australia
- Clinical Study Site — Brisbane, Queensland, Australia
- Clinical Study Site — Melbourne, Victoria, Australia
- Clinical Study Site — Antwerp, Belgium
- Clinical Study Site — Ranica, Italy
- Clinical Study Site — Leiden, Netherlands
- Clinical Study Site — Nijmegen, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.